Specifically, targeting screening to only patients with evidence of NAFLD or those with elevated ALT led to the most effective screening strategies, decreasing the need for liver biopsies while maintaining the same sensitivity. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.